RxDoctor Payments Data

Jeff Simerville, MD

Urology · Palmer, AKNPI 1871575506

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,045 of the $1,231 with a category attached, or 84.9%. 15 manufacturers reported payments, led by Boston Scientific at 36.5% of the total. That places this record below the midpoint for urology clinicians in AK, where the typical reported total is $2,491.

$1,231in general payments, 2019–2025

Across 44 payments — averaging $27.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$450
  • C. R. Bard, Inc. & Subsidiaries$180
  • Sumitomo Pharma America, Inc.$135
  • Astellas Pharma US Inc$118
  • Rochester Medical Corporation$76
  • Johnson & Johnson$61
  • plus $211 from 9 others

What the payments were for

  • Food & beverage$1,04585%
  • Education$18615%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,231 in reported general payments places this provider in the 35th percentile of 28 urology providers in Alaska.

See all urology providers in Alaska

Medicare billing

Part B allowed, 2024
$279,004
Medicare patients
594
Services billed
4,649

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron132$112,425
GemtesaVibegron20$14,755
Mirabegron ErMirabegron12$10,308
Tamsulosin Hcl332$7,879
Desmopressin Acetate32$6,325
Dutasteride52$2,757
Solifenacin Succinate48$2,632
Methenamine Hippurate16$2,211
Finasteride58$1,018
Bicalutamide11$934
Oxybutynin Chloride42$771
Tadalafil13$657
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst22$651
Alfuzosin Hcl ErAlfuzosin Hcl17$608
Silodosin12$600

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$118$112,425132 claims
Sumitomo Pharma America, Inc.Gemtesa$135$14,75520 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 28 urology providers in Alaska.

Other urology in Palmer

See the full list for Alaska

Where these figures come from

Is this you, or does something look wrong? →